September 19, 2017
Sonoran Biosciences announces completion of a Pre-IND Meeting for SBG002
Sonoran Biosciences, Inc., a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, today announced the completion of a Pre-IND meeting with the FDA Division of Anti-Infective Products regarding its lead product candidate, SBG002 which is being developed to facilitate the one-stage treatment of periprosthetic joint infection (PJI) of the hip or knee. Sonoran received clear feedback regarding the major manufacturing and nonclinical testing plans for SBG002 as well as the proposed Phase 1 clinical trial and certain regulatory matters. The company has incorporated the feedback from this meeting into its future development plans.
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, especially those that occur after surgery. The company’s lead product SBG002 is an injectable sustained-release gel containing tobramycin and vancomycin designed for direct application in surgical sites. SBG002 has the potential to become a first-in-class product for treatment and prevention of a wide variety of serious infections, and is being developed toward a lead indication in one-stage treatment of periprosthetic joint infection (PJI), the most common and costly reason for failed arthroplasty.